Drug

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
AbbVieNYSE: ABBV

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie Inc. (NYSE: ABBV) announced that China's National Medical Products Administration (NMPA) has approved RINVOQ (upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily) for the treatment of adults…

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Qilu Pharmaceutical's QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Qilu Pharmaceutical’s QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
MSD MK-2214 Fast Track Alzheimer Data Positive
Clinical trial resultsMerck Sharp & Dohme

MSD MK-2214 Fast Track Alzheimer Data Positive

Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients
Clinical trial approval / initiationGenerate Biomedicines

Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients

Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE
BiosimilarsHenlius Biotech

Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE

Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment
CancerKura Oncology

Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment

Show More